Abstract 417P
Background
Soft tissue sarcomas belong to a heterogeneous group of malignant tumours of mesenchymal origin which constitutes <1% of adult cancers and 12% of paediatric cancers. This study highlights the clinical spectrum of sarcomas, various histological patterns and survival outcomes. The intent is to study retrospectively the clinicopathologic profile and survival outcomes of soft tissue sarcomas and bone sarcomas treated with radiation therapy at a Regional Cancer Centre from South India.
Methods
The clinical and treatment details of patients were collected retrospectively for the period 2014 -2017 and were analysed using descriptive statistics. Survival analysis was done using Kaplan-Meir Analysis.
Results
The median age of presentation was 42 years (Range 2-80). Among the 123 patients studied , 54.5%(n = 67) were males and 45.5%(n = 56) were females. The most common presenting complaint was swelling 69% (n = 85) followed by pain 38.2% (n = 47). The most common site of involvement was extremity 48% (n = 59). Other more commonly involved sites were Genitourinary 7.3%(n = 9) and uterus 4.9% (n = 6). The most common histology was Ewing Sarcoma 14.6%(n = 18) followed by Undifferentiated Pleomorphic Sarcoma 13.8% (n = 17). Around 17.9%(n = 22) had metastatic disease at presentation, of which metastasis to lungs (n = 13) was most common, followed by bone (n = 8) and liver(n = 4). The intent of Radiation Therapy was Adjuvant 54.4%(n = 67), Palliative 32.2%(n = 21), Radical 13.8 (n = 17) and Neoadjuvant 6.5%(n = 8). Only 65.9%(n = 81) completed their intended radiation therapy. 91.9% (n = 113) received External Beam Radiation Therapy and 13% (n = 16) received Brachytherapy. Around 48.8% (n = 60) underwent surgery and 66.6% (n = 82) received some form of chemotherapy. The Mean Overall Survival was 50.4 months (95% CI 44.2-56.5 months). Median OS was not reached.
Conclusions
As per our study, the most common histology was Ewing Sarcoma, followed by Undifferentiated Pleomorphic sarcoma. Approximately 70% of sarcoma patients referred to Radiation Oncology department were for Curative intent whereas 30% with palliative intent and this has led to Mean OS of 50.4 months. At the same time with limited follow up data and the low number of events, the Median OS was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract